Epiminder to Present Four New Abstracts on the Minder® System at the 2025 American Epilepsy Society Annual Meeting
- Further analysis of the UMPIRE study demonstrates long-term safety, signal quality, seizure lateralization capabilities, and temporal pattern analysis with implantable continuous EEG monitoring
- Bilateral records allowing seizure lateralization is a significant differentiator for the Minder System when deploying continuous EEG monitoring strategies
Melbourne, Australia & Dallas, United States – December 5, 2025 – Epiminder Limited, a pioneer in implantable continuous EEG monitoring (iCEM®), today announced that four new abstracts evaluating the Minder System will be presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 5-9, 2025, in Atlanta, Georgia. These presentations showcase new clinical evidence demonstrating the long-term safety, signal quality, and diagnostic capabilities of the Minder System in patients with drug-resistant epilepsy. This work further underscores the Minder System capabilities and its ability to be entered into the clinical workflow for the management of drug-resistant epilepsy.
Minder System provides EEG signal quality comparable to gold-standard 10-20 scalp EEG recordings. Signal quality remained durable and consistent at both 4- and 24-weeks post-implantation, confirming the reliability of long-term seizure monitoring with the Minder System.
Lateralization of seizures is a significant differentiator of the Minder bilateral recording system and results from 14 patients revealed that the Minder System successfully identified seizure laterality in all cases, with four patients (29%) receiving different lateralization diagnoses compared to prior studies. A comparison of the 10-20 recorded seizures to Minder seizures showed the Minder had adequate signal quality to assess lateralisation of seizure onset in all cases. These findings have critical implications for surgical planning and patient selection for epilepsy resection procedures.
A third abstract presented demonstrated ten patients with previously diagnosed unilateral epilepsy revealed that 40% experienced a change in lateralization patterns during six months of continuous monitoring. The findings challenge traditional assumptions that seizure lateralization remains stable over time and underscore the importance of prolonged monitoring when considering surgical or device-based treatment options for drug-resistant epilepsy.
For the final abstract, long-term follow-up data from the landmark UMPIRE trial demonstrated the continued safety and performance of the Minder System for up to three years post-implantation. Twenty-two subjects continued into long-term follow-up, with no serious device- or procedure-related adverse events occurring at any point. Continuous high-quality EEG signals were maintained throughout the follow-up period. Patient-reported seizure severity showed statistically significant improvement compared to baseline measures.
Professor Mark Cook, Epiminder's Founder and Chief Medical Officer:
"These four abstracts collectively demonstrate that the Minder System provides safe, reliable, and clinically actionable continuous EEG monitoring over extended periods. The ability to capture months to years of high-quality EEG data is transforming our understanding of seizure patterns, lateralization stability, and long-term device safety in ways that were simply not possible with traditional short-duration monitoring approaches."
Dr. Rohan Hoare, Chief Executive Officer of Epiminder:
"These presentations at AES 2025 further validate the clinical utility of the Minder System and reinforce our commitment to advancing epilepsy care through continuous, long-term monitoring. Following our FDA authorization earlier this year, we are excited to bring these capabilities to clinicians and patients in the United States and around the world."
Media contacts: Mark Gardy 0412 376817 or Stephen Dabkowski 0419 880486
+++
Follow Epiminder on LinkedIn and explore epiminder.com for more information.
About Minder
Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Minder's long-term monitoring of patients outside of a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's condition, including determining the effectiveness of drug therapies and other interventions.
About Epiminder
Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.